Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed.
It was a busy week with lots of news, have a look and see you next week for another update.
Novamind to Host MindMed’s Phase 2b Trial
Novamind will host the LSD Clinical Trial at its Draper, Utah research site, further strengthening its track record of hosting neuropsychiatry and psychedelic clinical trials. In October 2021, Novamind was awarded two DEA Schedule 1 licenses for psilocybin research, qualifying it to conduct a recently announced phase II trial for major depressive disorder sponsored by the Usona Institute, as well as future psilocybin trials. Novamind expects to add LSD under the licenses in relation to the LSD Clinical Trial.
Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates
Bob Dagher, MD, Enveric’s Chief Medical Officer: “These patent applications aim to protect Enveric’s assets of new drug candidates and place our discovery engine at the forefront of bringing forward innovative psychiatric and neurologic therapeutics of the future.”
Global Wellness Institute Announces New Psychedelics Initiative
The Initiative will support collaboration and coalition building, and ethics and best practices, in the psychedelic community. High-profile lineup of members includes Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS)
HAVN Life Announces Distribution Deal with Jonluca Enterprises Inc.
The company is pleased to announce it has secured a distribution deal with Jonluca Enterprises Inc. for the company’s line of natural health products, launched in June of last year. The deal will enable HAVN Life products to be distributed nationally through purveyors of natural and organic products.
Awakn Life Sciences Announces New Clinic: A Closer Look
The company just announced the approval of its third treatment clinic. The future London clinic will join their current clinics in Bristol (UK) and Oslo (Norway), giving the company access to revenue and setting themselves up for future treatments of approved psychedelics, including already approved ketamine treatments
Clearmind Medicine Announces Positive Results on CMND-100 trials
Clearmind has announced promising results from two pre-clinical trials which tested suppression of alcohol consumption in mice using its novel psychedelic-based therapeutic CMND-100, whose active pharmaceutical ingredient is MEAI.
“We are excited to reveal that our proprietary CMND-100 showed very positive results that suggest strong potential for treating alcohol use disorder,” said Dr. Adi Zuloff-Shani, CEO of Clearmind.
Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed
